Onward Medical N.V. (63E.SG)

5.18 -0.02 (-0.38%) As of 08:05AM CEST. Market open.

Onward Medical N.V.

High Tech Campus 32
Eindhoven NL-5656
Netherlands

https://www.onwd.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 96

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David L. Marver	CEO & Director	961k	N/A	1968
Dr. Gregoire Courtine Ph.D.	Chief Scientific Officer & Director	N/A	N/A	1975
Mr. Khaled Bahi	Interim Chief Financial Officer	N/A	N/A	1966
Mr. Robert W. Odell	Vice President of Operations	N/A	N/A	1960
Mr. John Murphy	Chief Technology Officer	N/A	N/A	N/A
Sarah Moore	Vice President of Global Marketing	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARC-EX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation to treat upper extremity functional deficits with chronic tetraplegia. The company was founded in 2014 and is headquartered in Eindhoven, Netherlands.

Corporate governance

Onward Medical N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.